Long-term intraocular pressure changes after intravitreal injection of bevacizumab

Cutaneous and Ocular Toxicology

Volumn 35, Issue 4, 2016, Pages 310-314

  Baek, Sung Uk ^a   Park, In Won ^b   Suh, Wool ^b  

^a Department of Dermatology   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Bevacizumab; glaucoma; intraocular pressure

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR;

ADULT; AGE DISTRIBUTION; AGE RELATED MACULAR DEGENERATION; ARTICLE; CLINICAL ASSESSMENT; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; TREATMENT DURATION; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; DIABETIC COMPLICATION; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DIABETES COMPLICATIONS; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED;

EID: 84958037139     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2015.1124886     Document Type: Article

References (34)

1. M.Kliffen, H.S.Sharma, C.M.Mooy,. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154–162.
2. Research Group CATT. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–1908.
3. D.F.Martin, M.G.Maguire, S.L.Fine,. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration:two-year results. Ophthalmology 2012;119:1388–1398.
4. D.L.Epstein, P.V.Algvere, G.von Wendt,. Bevacizumab for macular edema in central retinal vein occlusion:a prospective, randomized, double-masked clinical study. Ophthalmology 2012;119:1184–1189.
5. B.C.Harder, F.C.Schlichtenbrede, S.von Baltz,. Intravitreal bevacizumab for retinopathy of prematurity:refractive error results. Am J Ophthalmol 2013;155:1119–1124.
6. J.D.Stein, P.A.Newman-Casey, D.D.Kim,. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology 2013;120:1835–1842.
7. J.J.Tseng, S.K.Vance, K.E.Della Torre,. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012;21:241–247.
8. R.A.Adelman, Q.Zheng, H.R.Mayer Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105–110.
9. T.J.Good, A.E.Kimura, N.Mandava, M.Y.Kahook Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111–1114.
10. M.Gismondi, C.Salati, M.L.Salvetat,. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009;18:658–661.
11. H.Hollands, J.Wong, R.Bruen,. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807–811.
12. J.E.Kim, A.V.Mantravadi, E.Y.Hur, D.J.Covert Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930–941.
13. S.J.Bakri, J.S.Pulido, C.A.McCannel,. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009;23:181–185.
14. M.Y.Kahook, A.E.Kimura, L.J.Wong,. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40:293–295.
15. S.J.Bakri, C.A.McCannel, A.O.Edwards, D.M.Moshfeghi Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955–958.
16. Y.J.Kim, K.R.Sung, K.S.Lee,. Long-term effects of multiple intravitreal antivascular endothelial growth factor injection on intraocular pressure. Am J Ophthalmol 2014;157:1266–1271.
17. Q.V.Hoang, L.S.Mendonca, K.E.Della Torre,. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012;119:321–326.
18. B.E.Klein, R.Klein, K.L.Linton Intraocular pressure in an American community. The Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 1992;33:2224–2248.
19. S.Y.Wu, M.C.Leske Associations with intraocular pressure in the Barbados Eye Study. Arch Ophthalmol 1997;115:1572–1576.
20. T.Nakano, M.Tatemichi, Y.Miura,. Long-term physiologic changes of intraocular pressure:a 10-year longitudinal analysis in young and middle-aged Japanese men. Ophthalmology 2005;112:609–616.
21. M.Engelbert, S.A.Zweifel, K.B.Freund “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009;29:1424–1431.
22. E.S.Gragoudas, A.P.Adamis, E.T.Cunningham, Jr,. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Eng J Med 2004;351:2805–2816.
23. VEGF Inhibition Study in Ocular Neovascularization (V. I. S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration:two-year safety results of the two prospective, multicenter, controlled clinical trials. Opthalmology 2006;113:992–1001.
24. L.Hyman Myopic and hyperopic refractive error in adults:an overview. Ophthalmic Epidemiol 2007;14:192–197.
25. S.M.Saw A synopsis of the prevalence rates and environmental risk factors for myopia. Clin Exp Optom 2003;86:289–294.
26. M.Georgopoulos, K.Polak, F.Prager,. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457–462.
27. L.Liu, D.A.Ammar, L.A.Ross,. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab:effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52:1023–1034.
28. Q.V.Hoang, J.J.Jung, S.Mrejen, K.B.Freund Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy. Retina 2014;34:519–524.
29. J.G.Ladas, F.Yu, R.Loo,. Relationship between aqueous humor protein level and outflow facility in patients with uveitis. Invest Ophthalmol Vis Sci 2001;42:2584–2588.
30. P.J.Rosenfeld, D.M.Brown, J.S.Heier,. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.
31. M.W.Stewart Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep 2014;14:510.
32. J.H.Liu, D.F.Kripke, M.D.Twa,. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci 1999;40:2912–2917.
33. G.R.Reiss, D.A.Lee, J.E.Topper, R.F.Brubaker Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci 1984;25:776–778.
34. N.Mathalone, A.Arodi-Golan, S.Sar,. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250:1435–1440.